{
  "docId": "019de073-dc46-770c-87a2-2b21d91043e5",
  "docSlug": "4f9fcbb83e828aea5419518c9cca9ae9",
  "documentTitle": "Tonix Pharmaceuticals | Investor Presentation Deck | 29 slides",
  "authorId": "tonix-pharmaceuticals",
  "authorName": "Tonix Pharmaceuticals",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 29,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "The slide uses checkmarks for completed items and empty squares for future items.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-dc46-770c-87a2-2b21d91043e5/26",
  "deckHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5",
  "deckJsonHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5.json",
  "deckAnchorHref": "/decks/019de073-dc46-770c-87a2-2b21d91043e5#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.5,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "*We cannot predict whether the global COVID-19 pandemic will impact the timing of these milestones.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6d4bc5f0-457c-49f7-9139-f4095e5fef9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.23
      },
      "kind": "list",
      "text": "2nd Quarter 2022: Phase 3 RESILIENT study start of TNX-102 SL for the management of fibromyalgia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f1c4b95-8ab0-4b43-9cb8-effdc32ea589",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.44
      },
      "kind": "list",
      "text": "2nd Quarter 2023: Interim analysis results of Phase 2 PREVAIL study of TNX-102 SL in Long COVID",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "447413e7-20d5-4c0c-abdd-0ee11046fc64",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "list",
      "text": "1st Quarter 2022: Topline data from Phase 3 RALLY study of TNX-102 SL for the management of fibromyalgia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6220eaae-4778-4d27-9f5b-7899c8188fa5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.7
      },
      "kind": "list",
      "text": "1st Quarter 2023: Phase 2 study start of TNX-601 ER for the treatment of major depressive disorder",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6247c53b-af0f-4128-8ff7-e287d099a2ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.39
      },
      "kind": "list",
      "text": "2nd Quarter 2023: Interim analysis results of Phase 3 RESILIENT study of TNX-102 SL in fibromyalgia",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "631786fa-b32b-4687-8852-722f6f65ad69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.55
      },
      "kind": "list",
      "text": "4th Quarter 2022: Phase 2 study start of TNX-102 SL for the treatment of PTSD in Kenya",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6cac5541-49a9-4fe3-a495-201d212879a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.6
      },
      "kind": "list",
      "text": "4th Quarter 2022: Phase 2 study start of TNX-1900 for the treatment of migraine",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "765cbb21-0f72-4c89-a931-4446b1d7454f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "list",
      "text": "1st Quarter 2023: Phase 2 study start of TNX-1300 for the treatment of cocaine intoxication",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7f252451-d415-4b85-822e-ce1555537b83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.75
      },
      "kind": "list",
      "text": "1st Half 2023: Phase 1 study start of TNX-1500 for prevention of allograft rejection",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc532d4d-b2bd-47b4-a9a0-50fa4118f56a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.28
      },
      "kind": "list",
      "text": "3rd Quarter 2022: Phase 2 PREVAIL study start of TNX-102 SL for the treatment of Long COVID",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f64b23fb-8bf9-4a2c-a4ef-718ded56f7e8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.75,
        "x": 0.04,
        "y": 0.8
      },
      "kind": "list",
      "text": "1st Half 2023: Phase 1 study start of TNX-801 for prevention of monkeypox and smallpox in Kenya",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff3e93cb-1bd6-49fb-b52e-989936749eeb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.04,
        "y": 0.51
      },
      "kind": "paragraph",
      "text": "Expected Clinical Trial Initiations",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06e9b598-b35c-4d0c-aa9e-9ddae5e0918f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.04,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "Expected Data",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b1afcae-e1cb-4dcc-af53-7f6fca130464",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.04,
        "y": 0.09
      },
      "kind": "title",
      "text": "Milestones: Recently Completed and Upcoming*",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "97d67eed-3c61-4b56-8c22-5edd32d1c2ef",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "gantt-chart",
      "slug": null,
      "matchId": "89e4d3ee-26fb-47ef-a349-378ba1f54661",
      "evidence": "The slide presents a chronological list of project milestones and expected start dates.",
      "confidence": 0.6
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "e532f435-d20e-4323-8595-44dab22c3ce1",
      "evidence": "The presentation uses a golden circle structure to communicate the company's mission and vision",
      "position": 0,
      "objective": "Why Tonix Pharmaceuticals?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}